EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Atomoxetine and risk of Alzheimer's disease in older adults

Adam P Bress, Yizhe Xu, Zachary A Marcum, Matthew Davis, Andrea Z LaCroix, Howard H Feldman, Aladdin H Shadyab iD

Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2026-10 · 12 (4)

DOI: 10.1002/trc2.70345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 16.11.2026. Verfasst von Adam P Bress und 6 weiteren Autor:innen. Beteiligte Einrichtung: Intermountain Healthcare Department of Population Health Sciences Divisions of Health System Innovation and Research and Biostatistics Spencer Fox-Ec…. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Experimental studies and a previous small, randomized trial suggest that atomoxetine, a selective norepinephrine reuptake inhibitor, may be efficacious in the prevention or disease modification of Alzheimer's disease (AD). Its association with incident AD is unclear. METHODS This non‐concurrent prospective study emulated a target trial among Medicare beneficiaries (January 1, 2007–December 31, 2023). The primary outcome was AD, determined using a validated algorithm. We estimated 5‐ and 10‐year risk ratios (RRs) and risk differences (RDs). Analyses were examined overall and by indication. RESULTS This study included 70,367 person‐trials (74.6% ≥70 years; 59.5% female; 86.7% non‐Hispanic White). Initiation of atomoxetine versus no initiation was not associated with 5‐ or 10‐year risk of AD but was associated with lower risk of AD‐free death. In indication‐specific analyses, atomoxetine was associated with lower 5‐year risk of AD and AD‐free death among individuals with depression. DISCUSSION Initiation of atomoxetine was not associated with lower risk of AD later in life. The lower risk of AD among people with depression warrants further study.

Schlagwörter

Stichwörter der Autor:innen

ADHDAlzheimer's diseaseMedicareatomoxetinedementiadepressiontarget trial emulation

Autor:innen und Institutionen

  • Intermountain Healthcare Department of Population Health Sciences Divisions of Health System Innovation and Research and Biostatistics Spencer Fox-Eccles School of Medicine University of Utah Salt Lake City Utah USA.
  • George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City Utah USA.
  • Division of Epidemiology Department of Internal Medicine Spencer Fox-Eccles School of Medicine University of Utah Salt Lake City Utah USA.
  • Medicus Economics, LLC Milton Massachusetts USA.
  • Herbert Wertheim School of Public Health and Human Longevity Science University of California San Diego La Jolla California USA.
  • Alzheimer's Disease Cooperative Study University of California San Diego School of Medicine La Jolla California USA.

ORCID-Profile: Aladdin H Shadyab

Zitieren

APA

Bress, A. P., Xu, Y., Marcum, Z. A., Davis, M., LaCroix, A. Z., Feldman, H. H., & Shadyab, A. H. (2026). Atomoxetine and risk of Alzheimer's disease in older adults. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 12(4). https://doi.org/10.1002/trc2.70345

Vancouver

Bress AP, Xu Y, Marcum ZA, Davis M, LaCroix AZ, Feldman HH, et al. Atomoxetine and risk of Alzheimer's disease in older adults. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2026;12(4). doi:10.1002/trc2.70345

BibTeX
@article{Bress2026,
  author = {Bress, Adam P and Xu, Yizhe and Marcum, Zachary A and Davis, Matthew and LaCroix, Andrea Z and Feldman, Howard H and Shadyab, Aladdin H},
  title = {Atomoxetine and risk of Alzheimer's disease in older adults},
  journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
  year = {2026},
  volume = {12},
  number = {4},
  doi = {10.1002/trc2.70345}
}
Kostenlos starten →